List of RNA Therapies Companies in Germany - 8

At baseclick GmbH we believe that bioconjugation is not just a method to connect (bio)molecules, but a tool to develop valuable applications. So, a new strategy was needed: click chemistry! " Nobel Prize 2022, the basis of the baseclick patented nucleic acid modification technology". We are a dynamic, highly professional team and enabling life science researchers to overcome challenges and create better solutions in diagnostics, therapeutics, and vaccines development through our proprietary click chemistry. Our mission is to develop and provide the best nucleic acid labeling applications and reagents for the life science market. For further information please visit our website https://www.baseclick.eu/ https://www.baseclick.eu/our-vaccine-strategy-and-its-benefits/

BioEcho Life Sciences is a specialized solution provider for the extraction and analysis of nucleic acids. We create disruptive technologies, products, and workflows that make downstream processing of nucleic acids easier and faster, significantly increase throughput, and deliver reliable results. Our EchoLUTION technology enables the fastest DNA and RNA extraction on the market - in just one single step. It reduces the associated plastic consumption by up to 70 %. Customers in molecular diagnostics, academic and biopharmaceutical research, plant and animal breeding rely on our products: ready-to-use kits, high-throughput solutions for automation platforms, nucleic acid extraction services and process optimization for molecular biology laboratories. BioEcho, located in Cologne, Germany, was founded in 2016 by leading industry experts and is certified according to ISO 9001 and ISO 13485. During the pandemic, our Viral RNA/DNA Swab kit was used in up to 15 % of Covid PCR tests in Germany and 50 % of tests in Austria. Through our European direct Sales team, our global distributor network, and our international online shop we serve a worldwide growing customer base with best-in-class products and services. BioEcho. The Nucleic Acid Experts. Follow us on LinkedIn so that we can keep you posted and get in touch via contact@bioecho.de.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

Pantherna Therapeutics is a privately held mRNA therapeutics company developing novel first-in-class therapies for indications with high unmet medical need. Pantherna’s development programs are based on two innovative and proprietary PTX platform technologies, offering robust mRNA expression constructs (PTXmRNA) and lipid nanoparticle (LNP) delivery vehicles (PTX_LNP) for localized expression of therapeutic proteins. PAN004 is Pantherna´s first development candidate derived from this platform, representing a defined mRNA-LNP formulation for selective mRNA delivery and expression of a Tie2-agonist in the vascular endothelium of the lung. Pantherna strives for expanding its pipeline with various novel mRNA-LNP candidates enabling the therapeutic use of mRNA beyond the vascular endothelium in distinct tissues such as skeletal muscle or immune cells.

We drive RNA research with tailored molecular tools. We are from Munich and provide researchers with highly complex & advanced genetic tools. Our core expertise is RNA interference, bioinformatics, and RNA research tools for RNA-Seq and Ribo-Seq. Distinguished by their exceptional targeting specificity and efficiency, our gene function analysis tools include - siPOOLTM for reliable gene silencing, raPOOLTM for targeted RNA affinity purification and riboPOOLTM for efficient ribosomal RNA depletion. Our technology combines high complexity oligo pooling (“Pack Hunter” approach), proprietary design algorithms, and quality production to achieve highly precise and rapid results. siTOOL’s reagents are used by Pharma for target discovery and validation and are mentioned in a growing list of academic publications. Comprised entirely of scientists, siTOOLs provides outstanding technical support and offers bespoke experimental and bioinformatic services, making it a favoured research partner for accelerating scientific discoveries and drug development.

We provide innovative gene editing reagents, screening services and engineered model systems for the global R&D market. Our success is based on the proprietary 3Cs technology.